Rare diseases
Investigational molecules
Locations
Recruiting trials first
5 clinical trials in this condition
France
DenmarkFrance
BulgariaIn short
Two clinical trials are currently investigating new treatment approaches for mucous membrane pemphigoid, a chronic autoimmune disorder that causes painful blistering of the mucous membranes. These studies are being conducted in Germany and France, testing both immune-modulating therapies and conventional immunosuppressive medications to help control disease activity and achieve remission.
This trial is being conducted in Germany and investigates a novel approach to treating several chronic inflammatory diseases, including mucous membrane pemphigoid. The study focuses on using low-dose Interleukin-2, also known as aldesleukin or IL-2, administered as an injection under the skin.
Who can participate: Patients with mild to moderate mucous membrane pemphigoid can join this study if their disease activity scores between 6 and 45 on the MMPDAI scale. Participants must be between 18 and 80 years old. The trial welcomes individuals who meet these specific disease activity criteria, ensuring that the treatment is tested on patients with appropriate levels of active disease.
Who cannot participate: The study excludes pregnant or breastfeeding women, individuals with severe allergic reactions to similar treatments, and those with active infections requiring treatment. People with a history of cancer within the last five years (except certain skin cancers), significant heart problems, uncontrolled high blood pressure, severe liver or kidney disease, or those who have received another investigational drug within 30 days are not eligible. Patients with a history of drug or alcohol abuse in the past year or those unable to comply with study procedures are also excluded.
What the trial aims to discover: The primary goal is to evaluate the safety and effectiveness of low-dose IL-2 therapy over an eight-week treatment period. Researchers want to understand how this medication affects the immune system and whether it leads to improvements in disease symptoms. The study will monitor participants' immune responses, specifically looking at whether the treatment can safely increase regulatory T cells, which help control inflammation in the body.
Investigational medication: The trial uses Interleukin-2 (IL-2) in low doses. This medication works by binding to specific receptors on T cells, promoting their growth and activity. The goal is to increase regulatory T cells in the body, which are important for controlling the immune system and reducing inflammation. This randomized, double-blind study means participants will be randomly assigned to treatment groups, and neither participants nor researchers will know who receives the actual medication or placebo during the study.
This French clinical trial specifically focuses on severe forms of mucous membrane pemphigoid and compares two different treatment approaches. The study tests rituximab, given as an intravenous infusion, against cyclophosphamide, taken as oral tablets, with both treatments used in combination with dapsone.
Who can participate: Patients aged 18 to 85 years with severe mucous membrane pemphigoid can join this study. The condition is considered severe if it involves eye disease threatening sight, narrowing of the throat or airways that could be life-threatening, involvement of areas that could scar and narrow, more than one mucous membrane area affected, severe mouth involvement, or skin or mouth involvement that hasn't improved with certain treatments. Participants must have up-to-date vaccinations, be part of a social security system, and be able to follow study procedures. Women of childbearing potential must agree to use effective birth control during the study and for 12 months after the last treatment, and men must agree to use condoms during the same period.
Who cannot participate: The trial excludes patients who do not have severe forms of the condition or who fall outside the specified age range. Individuals not part of the specified clinical trial groups or those considered part of vulnerable populations may also be excluded.
What the trial aims to discover: The study's main objective is to determine which treatment is more effective in achieving remission, meaning a reduction or disappearance of disease symptoms, over a 12-month period. Researchers will assess how well the treatments work in reducing disease activity and improving quality of life. The trial will also monitor safety by tracking side effects and adverse events, and will measure changes in specific antibodies in the blood associated with the disease to better understand how the treatments affect the underlying immune response.
Investigational medications: The trial tests two main medications. Rituximab is a monoclonal antibody administered through intravenous infusion at a dose of 500 mg. It works by targeting and reducing specific immune cells called B-cells, which are involved in the disease process. Cyclophosphamide is an alkylating agent taken orally in 50 mg doses. It works by interfering with the DNA of cells, preventing them from growing and dividing, which helps reduce immune system activity. Both treatments are combined with dapsone, a medication known for reducing inflammation. The study design allows researchers to compare these two approaches to determine which provides better outcomes for patients with severe disease.
The two ongoing clinical trials for mucous membrane pemphigoid represent different approaches to managing this challenging autoimmune disorder. The German study explores an innovative immune-modulating strategy using low-dose IL-2, suitable for patients with mild to moderate disease, while the French trial compares two established immunosuppressive treatments for patients with severe forms of the condition.
Geographically, opportunities for trial participation are currently limited to Western Europe, with one trial in Germany and one in France. The German study takes a broader approach, including multiple chronic inflammatory diseases in addition to mucous membrane pemphigoid, while the French study focuses exclusively on severe cases of this specific condition.
Both trials address important questions about treatment effectiveness and safety, with the German study emphasizing the potential of regulatory T cell enhancement and the French study directly comparing two standard treatment options. These studies may help expand treatment options and improve understanding of how different therapeutic approaches can benefit patients at various stages of disease severity.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
